Akero Therapeutics

AKRO | NASDAQ | 0 Obserwujący

$53.01

-0.65%

-$0.35

Obserwuj

Overview Metrics Financials

Fair Price

$42.51

Overvalued by 93.0%

Aby wyświetlić sprawiedliwą cenę akcji, musisz być członkiem Bulios Black.

Profile

Akero Therapeutics is a clinical-stage biotechnology company focused on developing therapeutic agents for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). Their lead drug, efruxifermin (EFX), is a bivalent Fc-FGF21 fusion protein designed to mimic the activity of the natural hormone FGF21, which regulates metabolism throughout the body. Akero is currently conducting clinical trials to further evaluate the efficacy and safety of this drug in treating advanced MASH.

Feed

There are no posts to show right now.

Akero Therapeutics

Fair Price

Profile

Feed

Zaloguj się do Bulios

Utwórz profil Bulios

Dlaczego Bulios?